

Pharmaceutical Management Agency

Section H Update for Hospital Pharmaceuticals

Effective 1 July 2016

Cumulative for April, May, June and July 2016



Contents

Summary of decisions effective 1 July 2016	3
Section H changes to Part II	8
Index	26

Summary of decisions

EFFECTIVE 1 JULY 2016

- Aciclovir (Lovir) tab dispersible 200 mg, 400 mg and 800 mg – price decrease and addition of HSS
- Amiloride hydrochloride (Apo-Amiloride) tab 5 mg – price decrease
- Amoxicillin (Apo-Amoxi) cap 250 mg and 500 mg – price decrease and addition of HSS
- Bortezomib (Velcade) inj 3.5 mg vial – addition of HSS
- Bortezomib (Velcade) inj 1 mg vial – to be delisted 1 September 2016
- Carmellose sodium with pectin and gelatine, paste and powder – amended chemical name
- Cefaclor (Ranbaxy-Cefaclor) grans for oral liq 25 mg per ml – addition of HSS
- Cefaclor (Ranbaxy-Cefaclor) cap 250 mg – price decrease and addition of HSS
- Cilazapril with hydrochlorothiazide (Apo-Cilazapril/Hydrochlorothiazide) tab 5 mg with hydrochlorothiazide 12.5 mg – price decrease and addition of HSS
- Clindamycin (Clindamycin ABM) cap 150 mg – price decrease and addition of HSS
- Clindamycin (Dalacin C) inj 150 mg per ml, 4 ml ampoule – price decrease and addition of HSS
- Clomiphene citrate (Mylan Clomiphen) tab 50 mg – new listing
- Dexamethasone phosphate (Max Health) inj 4 mg per ml, 1 ml and 2 ml ampoules – extension of HSS
- Dihydrocodeine tartrate (DHC Continus) tab long-acting 60 mg – price decrease and addition of HSS
- Dimercaptosuccinic acid (e.g. PCNZ, Optimus Healthcare, Chemet) cap 100 mg and 200 mg – amended example brands
- Dimethicone (healthE Dimethicone 5%) crm 5% tube, 100 g – price decrease and addition of HSS
- Dimethicone (healthE Dimethicone 5%) crm 5% pump bottle, 500 ml – price decrease and addition of HSS
- Dipyrindamole (Pytazen SR) tab long-acting 150 mg – addition of HSS
- Eptacog alfa [recombinant factor VIIA] (NovoSeven RT) inj 1 mg, 2 mg, 5 mg and 8 mg syringes – price increase
- Exemestane (Pfizer Exemestane) tab 25 mg – new listing and addition of HSS
- Exemestane (Aromasin) tab 25 mg – removal of HSS and to be delisted 1 January 2017

Summary of decisions – effective 1 July 2016 (continued)

- Fluconazole (Fluconazole-Claris) inj 2 mg per ml, 50 ml and 100 ml vial – addition of HSS
 - Glycopyrronium bromide (Max Health) inj 200 mcg per ml, 1 ml ampoule – extension of HSS
 - Itraconazole (Itrazole) cap 100 mg – price decrease and addition of HSS
 - Lactulose (Laevolac) oral liq 10 g per 15 ml – price decrease and addition of HSS
 - Lamotrigine (Motrig) tab dispersible 25 mg, 50 mg and 100 mg – new listing
 - Ledipasvir with sofosbuvir (Harvoni) tab 90 mg with sofosbuvir 400 mg – new listing
 - Levomepromazine hydrochloride (Wockhardt) inj 25 mg per ml, 1 ml ampoule – new listing and addition of HSS
 - Levomepromazine inj 25 mg per ml, 1 ml ampoule – presentation to be delisted 1 September 2016
 - Loperamide hydrochloride (Diamide Relief) cap 2 mg – price decrease and addition of HSS
 - Loratadine (Lorifix) tab 10 mg – price decrease and addition of HSS
 - Methotrexate (Methotrexate Sandoz) inj prefilled syringe 7.5 mg, 10 mg, 15 mg, 20 mg, 25 mg and 30 mg – price decrease
 - Metoprolol tartrate (Slow-Lopresor) tab long-acting 200 mg – price increase
 - Morphine sulphate (Arrow-Morphine LA) tab long-acting 10 mg, 30 mg, 60 mg and 100 mg – price decrease and addition of HSS
 - Neostigmine metilsulfate with glycopyrronium bromide (Max Health) inj 2.5 mg with glycopyrronium bromide 0.5 mg per ml, 1 ml ampoule – extension of HSS
 - Nivolumab (Opdivo) inj 10 mg per ml, 4 ml and 10 ml vials – new listing
 - Nortriptyline hydrochloride (Norpress) tab 10 mg and 25 mg – price decrease and addition of HSS
 - Omeprazole (Dr Reddy's Omeprazole) inj 40 mg ampoule with diluent – price increase and addition of HSS
 - Ondansetron (Ondansetron-Claris) inj 2 mg per ml, 2 ml ampoule – new listing and addition of HSS
 - Ondansetron (Ondansetron Kabi) inj 2 mg per ml, 4 ml ampoule – new listing and addition of HSS
 - Ondansetron (Ondanaccord) inj 2 mg per ml, 2 ml and 4 ml ampoules – to be delisted 1 September 2016
-

Summary of decisions – effective 1 July 2016 (continued)

- Oxybutynin (Apo-Oxybutynin) tab 5 mg – price decrease and addition of HSS
 - Oxybutynin (Apo-Oxybutynin) oral liq 5 mg per 5 ml – price increase and addition of HSS
 - Oxycodone hydrochloride (BNM) tab controlled-release 5 mg, 10 mg, 20 mg, 40 mg and 80 mg – new listing and addition of HSS
 - Oxycodone hydrochloride (Oxycontin) tab controlled-release 5 mg – to be delisted 1 September 2016
 - Oxycodone hydrochloride (Oxycodone Controlled Release Tablets (BNM)) tab controlled-release 10 mg, 20 mg, 40 mg and 80 mg – to be delisted 1 September 2016
 - Paritaprevir, ritonavir and ombitasvir with dasabuvir (Viekira Pak) tab 75 mg with ritonavir 50 mg, and ombitasvir 12.5 mg (56), with dasabuvir tab 250 mg (56) – new listing
 - Paritaprevir, ritonavir and ombitasvir with dasabuvir and ribavirin (Viekira Pak-RBV) tab 75 mg with ritonavir 50 mg, and ombitasvir 12.5 mg (56), with dasabuvir tab 250 mg (56) and ribavirin tab 200 mg (168) – new listing
 - Phenoxyethylpenicillin [penicillin V] (AFT) grans for oral liq 125 mg per 5 ml and 250 mg per 5 ml – price decrease and addition of HSS
 - Pramipexole hydrochloride (Ramipex) tab 0.25 mg and 1 mg – addition of HSS
 - Rituximab (Mabthera) inj 10 mg per ml, 10 ml and 50 ml vial – amended restriction
 - Ropinirole hydrochloride (Apo-Ropinirole) tab 0.25 mg – price increase and addition of HSS
 - Ropinirole hydrochloride (Apo-Ropinirole) tab 1 mg – price decrease and addition of HSS
 - Ropinirole hydrochloride (Apo-Ropinirole) tab 2 mg – addition of HSS
 - Ropinirole hydrochloride (Apo-Ropinirole) tab 5 mg – price increase and addition of HSS
 - Sertraline (Arrow-Sertraline) tab 50 mg and 100 mg – price decrease and addition of HSS
 - Sirolimus (Rapamune) tab 1 mg and 2 mg, and oral liq 1 mg per ml – price decrease
 - Sodium chloride (Baxter) inj 0.45%, 500 ml bag, 18 bag pack – new listing and addition of HSS
 - Sodium chloride (Baxter) inj 0.45%, 500 ml bag, 1 bag pack – to be delisted 1 September 2016
-

Summary of decisions – effective 1 July 2016 (continued)

- Sodium chloride (Baxter) inj 0.9%, 50 ml bag, 60 bag pack – new listing and addition of HSS
- Sodium chloride (Baxter) inj 0.9%, 50 ml bag, 1 bag pack – to be delisted 1 September 2016
- Sodium chloride (Baxter) inj 0.9%, 100 ml bag, 48 bag pack – new listing and addition of HSS
- Sodium chloride (Baxter) inj 0.9%, 100 ml bag, 1 bag pack – to be delisted 1 September 2016
- Sodium chloride (Baxter) inj 0.9%, 250 ml bag, 24 bag pack – new listing and addition of HSS
- Sodium chloride (Baxter) inj 0.9%, 250 ml bag, 1 bag pack – to be delisted 1 September 2016
- Sodium chloride (Baxter) inj 0.9%, 500 ml bag, 18 bag pack – new listing and addition of HSS
- Sodium chloride (Baxter and Freeflex) inj 0.9%, 500 ml bag, 1 bag pack – to be delisted 1 September 2016
- Sodium chloride (Baxter) inj 0.9%, 1,000 ml bag, 12 bag pack – new listing and addition of HSS
- Sodium chloride (Baxter and Freeflex) inj 0.9%, 1,000 ml bag, 1 bag pack – to be delisted 1 September 2016
- Sodium chloride (Baxter) inj 3%, 1,000 ml bag, 12 bag pack – new listing and addition of HSS
- Sodium chloride (Baxter) inj 3%, 1,000 ml bag, 1 bag pack – to be delisted 1 September 2016
- Sodium hyaluronate [hyaluronic acid] (Healon GV) inj 14 mg per ml, 0.85 ml and 0.55 ml syringes – addition of HSS
- Sodium hyaluronate [hyaluronic acid] (Healon 5) inj 23 mg per ml, 0.6 ml syringe – new listing and addition of HSS
- Sodium hyaluronate [hyaluronic acid] (Healon) inj 10 mg per ml, 0.85 ml syringe – new listing and addition of HSS
- Sodium hyaluronate [hyaluronic acid] (Provisc) inj 10 mg per ml, 0.85 ml syringe – to be delisted 1 September 2016
- Sodium hyaluronate [hyaluronic acid] with chondroitin sulphate (Duovisc) inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.5 ml syringe and inj 10 mg sodium hyaluronate [hyaluronic acid] per ml, 0.55 ml syringe – addition of HSS

Summary of decisions – effective 1 July 2016 (continued)

- Sodium hyaluronate [hyaluronic acid] with chondroitin sulphate (Viscoat) inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.75 ml syringe – amended presentation, new listing and addition of HSS
- Sodium phenylbutyrate (Pheburane) grans 483 mg per g, 174 g – new listing
- Tenoxicam (Tilcotil) tab 20 mg – new listing and addition of HSS
- Tenoxicam (Reutenox) tab 20 mg – to be delisted 1 September 2016
- Terazosin (Actavis) tab 1 mg – price increase, addition of HSS and amended brand name
- Tetrabenazine (Motetis) tab 25 mg – price decrease and addition of HSS
- Tetracosactide [tetracosactrin] inj 250 mcg per ml, 1 ml ampoule (Synacthen) and inj 1 mg per ml, 1 ml ampoule (Synacthen Depot) – price increase
- Timolol (Timoptol XE) eye drops gel forming 0.25% and 0.5% – addition of HSS
- Tiotropium bromide soln for inhalation 2.5 mcg per dose (Spiriva Respimat) and powder for inhalation 18 mcg per dose (Spiriva) – price decrease
- Tranexamic acid (Cyklokapron) tab 500 mg – price decrease and addition of HSS
- Urea (healthE Urea Cream) crm 10%, 100 g – new listing and addition of HSS
- Verapamil hydrochloride (Isoptin) inj 2.5 mg per ml, 2 ml ampoule – price increase
- Voriconazole (Vfend) powder for oral suspension 40 mg per ml – amended presentation and price increase
- Water (Baxter) inj 1,000 ml bag, 12 bag pack – new listing and addition of HSS
- Water (Baxter) inj 1,000 ml bag, 1 bag pack – to be delisted 1 September 2016
- Zidovudine [AZT] (Retrovir) cap 100 mg and oral liq 10 mg per ml – addition of HSS

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Section H changes to Part II

Effective 1 July 2016

ALIMENTARY TRACT AND METABOLISM

13	LOPERAMIDE HYDROCHLORIDE (↓ price and addition of HSS) Cap 2 mg – 1% DV Sep-16 to 2019	7.05	400	Diamide Relief
15	GLYCOPYRRONIUM BROMIDE (extension of HSS) Inj 200 mcg per ml, 1 ml ampoule – 1% DV Jul-16 to 2019.....	17.14	10	Max Health
16	OMEPRAZOLE (↑ price and addition of HSS) Inj 40 mg ampoule with diluent – 1% DV Sep-16 to 2019	33.98	5	Dr Reddy's Omeprazole
20	LACTULOSE (↓ price and addition of HSS) Oral liq 10 g per 15 ml – 1% DV Sep-16 to 2019	3.18	500 ml	Laevolac
21	SODIUM PHENYLBUTYRATE (new listing) → Grans 483 mg per g.....	1,920.00	174 g	Pheburane
	Restricted Initiation Metabolic physician <i>Re-assessment required after 12 months</i> For the chronic management of a urea cycle disorder involving a deficiency of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinate synthetase. Continuation Metabolic physician <i>Re-assessment required after 12 months</i> The treatment remains appropriate and the patient is benefiting from treatment.			
23	CARMELLOSE SODIUM SODIUM CARBOXYMETHYLCELLULOSE WITH PECTIN AND GELATINE (amended chemical name) Paste Powder			

BLOOD AND BLOOD FORMING ORGANS

30	EPTACOG ALFA [RECOMBINANT FACTOR VIIA] (↑ price) → Inj 1 mg syringe..... → Inj 2 mg syringe..... → Inj 5 mg syringe..... → Inj 8 mg syringe.....	1,178.30 2,356.60 5,891.50 9,426.40	1 1 1 1	NovoSeven RT NovoSeven RT NovoSeven RT NovoSeven RT
30	TRANEXAMIC ACID (↓ price and addition of HSS) Tab 500 mg – 1% DV Sep-16 to 2019	20.67	100	Cyklokapron
34	DIPYRIDAMOLE (addition of HSS) Tab long-acting 150 mg – 1% DV Sep-16 to 2019	11.52	60	Pytazen SR

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 July 2016 (continued)

37	SODIUM CHLORIDE (pack change and addition of HSS)			
	Inj 0.45%, 500 ml bag – 1% DV Sep-16 to 2019	71.28	18	Baxter
	Inj 0.9%, 50 ml bag – 1% DV Sep-16 to 2019	109.80	60	Baxter
	Inj 0.9%, 100 ml bag – 1% DV Sep-16 to 2019	78.24	48	Baxter
	Inj 0.9%, 250 ml bag – 1% DV Sep-16 to 2019	44.64	24	Baxter
	Inj 0.9%, 500 ml bag – 1% DV Sep-16 to 2019	22.14	18	Baxter
	Inj 0.9%, 1,000 ml bag – 1% DV Sep-16 to 2019	15.12	12	Baxter
	Inj 3%, 1,000 ml bag – 1% DV Sep-16 to 2019	91.20	12	Baxter
	Note – Baxter sodium chloride inj 0.45%, inj 0.9% and inj 3% single bags to be delisted 1 September 2016.			
	Note – Freeflex sodium chloride inj 0.9% to be delisted 1 September 2016.			
38	WATER (pack change and addition of HSS)			
	Inj, 1,000 ml bag – 1% DV Sep-16 to 2019	19.08	12	Baxter
	Note – Baxter water inj, single bags to be delisted 1 September 2016.			

CARDIOVASCULAR SYSTEM

39	CILAZAPRIL WITH HYDROCHLOROTHIAZIDE (↓ price and addition of HSS)			
	Tab 5 mg with hydrochlorothiazide 12.5 mg – 1% DV Sep-16 to 2019	10.18	100	Apo-Cilazapril/ Hydrochlorothiazide
40	TERAZOSIN (↑ price, addition of HSS and amended brand name)			
	Tab 1 mg – 1% DV Sep-16 to 2019	0.59	28	Actavis Arrow
42	METOPROLOL TARTRATE (↑ price)			
	Tab long-acting 200 mg	23.40	28	Slow-Lopresor
44	VERAPAMIL HYDROCHLORIDE (↑ price)			
	Inj 2.5 mg per ml, 2 ml ampoule	25.00	5	Isoptin
45	AMILORIDE HYDROCHLORIDE (↓ price)			
	Tab 5 mg	15.00	100	Apo-Amiloride

DERMATOLOGICALS

52	DIMETHICONE (↓ price and addition of HSS)			
	Crm 5% tube – 1% DV Sep-16 to 2019	1.59	100 g	healthE Dimethicone 5%
	Crm 5% pump bottle – 1% DV Sep-16 to 2019	4.59	500 ml	healthE Dimethicone 5%
53	UREA (new listing and addition of HSS)			
	Crm 10% – 1% DV Sep-16 to 2019	1.37	100 g	healthE Urea Cream

GENITO-URINARY SYSTEM

60	OXYBUTYNIN (addition of HSS)			
	Tab 5 mg – 1% DV Sep-16 to 2019 (↓ price)	8.85	500	Apo-Oxybutynin
	Oral liq 5 mg per 5 ml – 1% DV Sep-16 to 2019 (↑ price)	60.40	473 ml	Apo-Oxybutynin

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 July 2016 (continued)

HORMONE PREPARATIONS

62	DEXAMETHASONE PHOSPHATE (extension of HSS)			
	Inj 4 mg per ml, 1 ml ampoule – 1% DV Jul-16 to 2019	14.19	10	Max Health
	Inj 4 mg per ml, 2 ml ampoule – 1% DV Jul-16 to 2019	12.59	5	Max Health
63	CLOMIPHENE CITRATE (new listing)			
	Tab 50 mg	29.84	10	Mylan Clomiphen
64	TETRACOSACTIDE [TETRACOSACTRIN] (↑ price)			
	Inj 250 mcg per ml, 1 ml ampoule	75.00	1	Synacthen
	Inj 1 mg per ml, 1 ml ampoule	690.00	1	Synacthen Depot

INFECTIONS

72	CEFACLOR (addition of HSS)			
	Grans for oral liq 25 mg per ml – 1% DV Sep-16 to 2019	3.53	100 ml	Ranbaxy-Cefaclor
72	CEFACLOR (↓ price and addition of HSS)			
	Cap 250 mg – 1% DV Sep-16 to 2019	24.70	100	Ranbaxy-Cefaclor
74	AMOXICILLIN (↓ price and addition of HSS)			
	Cap 250 mg – 1% DV Sep-16 to 2019	14.97	500	Apo-Amoxi
	Cap 500 mg – 1% DV Sep-16 to 2019	16.75	500	Apo-Amoxi
74	PHENOXYMETHYLPENICILLIN [PENICILLIN V] (↓ price and addition of HSS)			
	Grans for oral liq 125 mg per 5 ml – 1% DV Sep-16 to 2019	1.48	100 ml	AFT
	Grans for oral liq 250 mg per 5 ml – 1% DV Sep-16 to 2019	1.58	100 ml	AFT
76	CLINDAMYCIN (↓ price and addition of HSS)			
	→ Cap 150 mg – 1% DV Sep-16 to 2019	4.10	16	Clindamycin ABM
	→ Inj 150 mg per ml, 4 ml ampoule – 1% DV Sep-16 to 2019	65.00	10	Dalacin C
78	FLUCONAZOLE (addition of HSS)			
	→ Inj 2 mg per ml, 50 ml vial – 1% DV Sep-16 to 2019	4.95	1	Fluconazole-Claris
	→ Inj 2 mg per ml, 100 ml vial – 1% DV Sep-16 to 2019	6.47	1	Fluconazole-Claris
78	ITRACONAZOLE (↓ price and addition of HSS)			
	→ Cap 100 mg – 1% DV Sep-16 to 2019	2.79	15	Itrazole
79	VORICONAZOLE (amended presentation and ↑ price)			
	→ Powder for oral suspension Oral liq 40 mg per ml	876.00	70 ml	Vfend
85	ZIDOVUDINE [AZT] (addition of HSS)			
	→ Cap 100 mg – 1% DV Sep-16 to 2019	152.25	100	Retrovir
	→ Oral liq 10 mg per ml – 1% DV Sep-16 to 2019	30.45	200 ml	Retrovir

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 July 2016 (continued)

90	LEDIPASVIR WITH SOFOSBUVIR (new listing) → Tab 90 mg with sofosbuvir 400 mg	24,363.46	28	Harvoni
	Restricted Only for use in patients with approval by the Hepatitis C Treatment Panel (HepCTP). Applications will be considered by HepCTP at its regular meetings and approved subject to eligibility according to the Access Criteria (set out in Section B of the Pharmaceutical Schedule).			
90	PARITAPREVIR, RITONAVIR AND OMBITASVIR WITH DASABUVIR (new listing) Tab 75 mg with ritonavir 50 mg, and ombitasvir 12.5 mg (56), with dasabuvir tab 250 mg (56)	16,500.00	1	Viekira Pak
	Note only for use in patients who have received supply of treatment via PHARMAC's approved direct distribution supply. Application details for accessing treatment may be obtained from PHARMAC's website http://www.pharmac.govt.nz			
90	PARITAPREVIR, RITONAVIR AND OMBITASVIR WITH DASABUVIR AND RIBAVIRIN (new listing) Tab 75 mg with ritonavir 50 mg, and ombitasvir 12.5 mg (56), with dasabuvir tab 250 mg (56) and ribavirin tab 200 mg (168)	16,500.00	1	Viekira Pak-RBV
	Note only for use in patients who have received supply of treatment via PHARMAC's approved direct distribution supply. Application details for accessing treatment may be obtained from PHARMAC's website http://www.pharmac.govt.nz			
103	ACICLOVIR (↓ price and addition of HSS) → Tab dispersible 200 mg – 1% DV Sep-16 to 2019	1.60	25	Lovir
	→ Tab dispersible 400 mg – 1% DV Sep-16 to 2019	5.38	56	Lovir
	→ Tab dispersible 800 mg – 1% DV Sep-16 to 2019	5.98	35	Lovir

MUSCULOSKELETAL SYSTEM

95	NEOSTIGMINE METILSULFATE WITH GLYCOPYRRONIUM BROMIDE (extension of HSS) Inj 2.5 mg with glycopyrronium bromide 0.5 mg per ml, 1 ml ampoule – 1% DV Jul-16 to 2019	20.90	10	Max Health
----	---	-------	----	------------

NERVOUS SYSTEM

104	TENOXCAM (brand change) Tab 20 mg – 1% DV Sep-16 to 2019	10.95	100	Tilcotil
	Note – Reutenox tab 20 mg to be delisted from 1 September 2016.			
105	TETRABENAZINE (↓ price and addition of HSS) Tab 25 mg – 1% DV Sep-16 to 2019	91.10	112	Motetis
106	PRAMIPEXOLE HYDROCHLORIDE (addition of HSS) Tab 0.25 mg – 1% DV Sep-16 to 2019	7.20	100	Ramipex
	Tab 1 mg – 1% DV Sep-16 to 2019	24.39	100	Ramipex
106	ROPINIROLE HYDROCHLORIDE (addition of HSS) Tab 2 mg – 1% DV Sep-16 to 2019	7.72	100	Apo-Ropinirole

		Price (ex man. Excl. GST)		Brand or Generic Manufacturer
		\$	Per	
Changes to Section H Part II – effective 1 July 2016 (continued)				
106	ROPINIROLE HYDROCHLORIDE (↓ price and addition of HSS) Tab 1 mg – 1% DV Sep-16 to 2019	5.00	100	Apo-Ropinirole
106	ROPINIROLE HYDROCHLORIDE (↑ price and addition of HSS) Tab 0.25 mg – 1% DV Sep-16 to 2019	2.78	100	Apo-Ropinirole
	Tab 5 mg – 1% DV Sep-16 to 2019	16.51	100	Apo-Ropinirole
110	DIHYDROCODEINE TARTRATE (↓ price and addition of HSS) Tab long-acting 60 mg – 1% DV Sep-16 to 2019	9.55	60	DHC Continus
111	MORPHINE SULPHATE (↓ price and addition of HSS) Tab long-acting 10 mg – 1% DV Sep-16 to 2019	1.93	10	Arrow-Morphine LA
	Tab long-acting 30 mg – 1% DV Sep-16 to 2019	2.85	10	Arrow-Morphine LA
	Tab long-acting 60 mg – 1% DV Sep-16 to 2019	5.60	10	Arrow-Morphine LA
	Tab long-acting 100 mg – 1% DV Sep-16 to 2019	6.10	10	Arrow-Morphine LA
112	OXYCODONE HYDROCHLORIDE (brand change) Tab controlled-release 5 mg – 1% DV Sep-16 to 2018	2.63	20	BNM
	Tab controlled-release 10 mg – 1% DV Sep-16 to 2018	2.76	20	BNM
	Tab controlled-release 20 mg – 1% DV Sep-16 to 2018	4.72	20	BNM
	Tab controlled-release 40 mg – 1% DV Sep-16 to 2018	7.69	20	BNM
	Tab controlled-release 80 mg – 1% DV Sep-16 to 2018	14.11	20	BNM
Note – Oxycotin tab controlled-release 5 mg to be delisted from 1 September 2016. Note – Oxycodone Controlled Release Tablets (BNM) tab controlled-release 10 mg, 20 mg, 40 mg and 80 mg to be delisted from 1 September 2016.				
113	NORTRIPTYLINE HYDROCHLORIDE (↓ price and addition of HSS) Tab 10 mg – 1% DV Sep-16 to 2019	3.22	100	Norpress
	Tab 25 mg – 1% DV Sep-16 to 2019	7.08	180	Norpress
114	SERTRALINE (↓ price and addition of HSS) Tab 50 mg – 1% DV Sep-16 to 2019	3.05	90	Arrow-Sertraline
	Tab 100 mg – 1% DV Sep-16 to 2019	5.25	90	Arrow-Sertraline
117	LAMOTRIGINE (new listing) Tab dispersible 25 mg	14.74	56	Motrig
	Tab dispersible 50 mg	24.73	56	Motrig
	Tab dispersible 100 mg	42.34	56	Motrig
120	ONDANSETRON (brand change) Inj 2 mg per ml, 2 ml ampoule – 1% DV Sep-16 to 2019	1.50	5	Ondansetron-Claris
	Inj 2 mg per ml, 4 ml ampoule – 1% DV Sep-16 to 2019	2.20	5	Ondansetron Kabi
Note – Ondanaccord inj 2 mg per ml, 2 ml and 4 ml ampoules to be delisted 1 September 2016.				
122	LEVOMEPRMAZINE HYDROCHLORIDE (new listing and addition of HSS) Inj 25 mg per ml, 1 ml ampoule – 1% DV Sep-16 to 2019	47.89	10	Wockhardt
Note – levomepromazine inj 25 mg per ml, 1 ml ampoule to be delisted from 1 September 2016.				

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 July 2016 (continued)

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

134	METHOTREXATE (↓ price)			
	Inj 7.5 mg prefilled syringe.....	14.61	1	Methotrexate Sandoz
	Inj 10 mg prefilled syringe.....	14.66	1	Methotrexate Sandoz
	Inj 15 mg prefilled syringe.....	14.77	1	Methotrexate Sandoz
	Inj 20 mg prefilled syringe.....	14.88	1	Methotrexate Sandoz
	Inj 25 mg prefilled syringe.....	14.99	1	Methotrexate Sandoz
	Inj 30 mg prefilled syringe.....	15.09	1	Methotrexate Sandoz
134	BORTEZOMIB (addition of HSS)			
	→ Inj 3.5 mg vial – 1% DV Jul-16 to 2019	1,892.50	1	Velcade
	Note – Velcade inj 1 mg vial to be delisted from 1 September 2016.			
145	EXEMESTANE (new listing and transfer of HSS)			
	Tab 25 mg – 1% DV Jul-16 to 2017	14.50	30	Pfizer Exemestane
145	EXEMESTANE (delisting)			
	Tab 25 mg – 1% DV Sep-14 to 2017 30/6/16	14.50	30	Aromasin
	Note – Aromasin tab 25 mg to be delisted from 1 January 2017.			
163	NIVOLUMAB (new listing)			
	→ Inj 10 mg per ml, 4 ml vial.....	1,051.98	1	Opdivo
	→ Inj 10 mg per ml, 10 ml vial.....	2,629.96	1	Opdivo
	Restricted			
	Initiation			
	Medical oncologist			
	<i>Re-assessment required after 4 months</i>			
	All of the following:			
	1 Patient has metastatic or unresectable melanoma stage III or IV; and			
	2 Patient has measurable disease as defined by the presence of at least one CT or MRI measurable lesion; and			
	3 Nivolumab is to be used at a maximum dose of 3 mg/kg every 2 weeks for a maximum of 12 weeks (6 cycles); and			
	4 Baseline measurement of overall tumour burden is documented (see Note); and			
	5 Documentation confirming that the patient has been informed and acknowledges that the initial funded treatment period of nivolumab will not be continued beyond 12 weeks if their disease progresses during this time.			
	Continuation			
	Medical oncologist			
	<i>Re-assessment required after 4 months</i>			
	All of the following:			
	1 Any of the following:			
	1.1 Patient's disease has had a complete response to treatment according to RECIST criteria (see Note); or			
	1.2 Patient's disease has had a partial response to treatment according to RECIST criteria (see Note); or			
	1.3 Patient has stable disease according to RECIST criteria (see Note); and			
	2 Response to treatment in target lesions has been determined by radiologic assessment (CT or MRI scan) following the most recent treatment period; and			
	3 No evidence of progressive disease according to RECIST criteria (see Note); and			
	4 The treatment remains clinically appropriate and the patient is benefitting from the treatment; and			
	5 Nivolumab will be used at a maximum dose of 3 mg/kg every 2 weeks for a maximum of 12 weeks (6 cycles).			

continued...

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 July 2016 (continued)

continued...

Notes:

Disease responses to be assessed according to the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 (Eisenhauer EA, et al. Eur J Cancer 2009;45:228-47). Assessments of overall tumour burden and measurable disease to be undertaken on a minimum of one lesion and maximum of 5 target lesions (maximum two lesions per organ). Target lesions should be selected on the basis of their size (lesions with the longest diameter), be representative of all involved organs, and suitable for reproducible repeated measurements. Target lesion measurements should be assessed using CT or MRI imaging with the same method of assessment and the same technique used to characterise each identified and reported lesion at baseline and every 12 weeks.

Response definitions as follows:

- Complete Response: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm.
- Partial Response: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
- Progressive Disease: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
- Stable Disease: Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease.

164	RITUXIMAB (amended restriction – new criteria shown only)		
	→ Inj 10 mg per ml, 10 ml vial.....	1,075.50	2
	→ Inj 10 mg per ml, 50 ml vial.....	2,688.30	1

Mabthera
Mabthera

**Initiation – Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS)
Nephrologist**

Limited to 4 weeks treatment

All of the following:

1. Patient is a child with SDNS* or FRNS*; and
2. Treatment with steroids for at least a period of 3 months has been ineffective or associated with evidence of steroid toxicity; and
3. Treatment with ciclosporin for at least a period of 3 months has been ineffective and or discontinued due to unacceptable side effects; and
4. Treatment with mycophenolate for at least a period of 3 months with no reduction in disease relapses; and
5. The total rituximab dose used would not exceed the equivalent of 375 mg/ m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with a * are Unapproved indications.

**Continuation – Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS)
Nephrologist**

Limited to 4 weeks treatment

All of the following:

1. Patient who was previously treated with rituximab for nephrotic syndrome*; and
2. Treatment with rituximab was previously successful and has demonstrated sustained response for >6 months, but the condition has relapsed and the patient now requires repeat treatment; and
3. The total rituximab dose used would not exceed the equivalent of 375 mg/ m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with a * are Unapproved indications.

continued...

→ Restriction
(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 July 2016 (continued)
continued...

Initiation – Steroid resistant nephrotic syndrome (SRNS)

Nephrologist

Limited to 4 weeks treatment

All of the following:

1. Patient is a child with SRNS* where treatment with steroids and ciclosporin for at least 3 months have been ineffective; and
2. Treatment with tacrolimus for at least 3 months has been ineffective; and
3. Genetic causes of nephrotic syndrome have been excluded; and
4. The total rituximab dose used would not exceed the equivalent of 375 mg/ m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with a * are Unapproved indications.

Continuation – Steroid resistant nephrotic syndrome (SRNS)

Nephrologist

Limited to 4 weeks treatment

All of the following:

1. Patient who was previously treated with rituximab for nephrotic syndrome*; and
2. Treatment with rituximab was previously successful and has demonstrated sustained response for greater than 6 months, but the condition has relapsed and the patient now requires repeat treatment; and
3. The total rituximab dose used would not exceed the equivalent of 375 mg/ m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with a * are Unapproved indications.

174	SIROLIMUS (↓ price)			
	→ Tab 1 mg	749.99	100	Rapamune
	→ Tab 2 mg	1,499.99	100	Rapamune
	→ Oral liq 1 mg per ml	449.99	60 ml	Rapamune

RESPIRATORY SYSTEM AND ALLERGIES

177	LORATADINE (↓ price and addition of HSS)			
	Tab 10 mg – 1% DV Sep-16 to 2019	1.28	100	Lorafix
178	TIOTROPIUM BROMIDE (↓ price)			
	Note: tiotropium treatment must not be used if the patient is also receiving treatment with subsidised inhaled glycopyrronium or umeclidinium.			
	→ Soln for inhalation 2.5 mcg per dose	50.37	60 dose	Spiriva Respimat
	→ Powder for inhalation 18 mcg per dose	50.37	30 dose	Spiriva

SENSORY ORGANS

186	SODIUM HYALURONATE [HYALURONIC ACID] (addition of HSS)			
	Inj 14 mg per ml, 0.85 ml syringe – 1% DV Sep-16 to 2019	50.00	1	Healon GV
	Inj 14 mg per ml, 0.55 ml syringe – 1% DV Sep-16 to 2019	50.00	1	Healon GV
186	SODIUM HYALURONATE [HYALURONIC ACID] (new listing)			
	Inj 23 mg per ml, 0.6 ml syringe – 1% DV Sep-16 to 2019	60.00	1	Healon 5
186	SODIUM HYALURONATE [HYALURONIC ACID] (brand change)			
	Inj 10 mg per ml, 0.85 ml syringe – 1% DV Sep-16 to 2019	28.50	1	Healon
	Note – Provisc inj 10 mg per ml, 0.85 ml syringe to be delisted from 1 September 2016.			

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 July 2016 (continued)

186	SODIUM HYALURONATE [HYALURONIC ACID] WITH CHONDROITIN SULPHATE (addition of HSS) Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.5 ml syringe and inj 10 mg sodium hyaluronate [hyaluronic acid] per ml, 0.55 ml syringe – 1% DV Sep-16 to 2019	74.00	1	Duovisc
186	SODIUM HYALURONATE [HYALURONIC ACID] WITH CHONDROITIN SULPHATE (amended presentation description and new listing) Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.75 ml syringe – 1% DV Sep-16 to 2019	67.00	1	Viscoat
186	TIMOLOL (addition of HSS) Eye drops 0.25%, gel forming – 1% DV Sep-16 to 2019	3.30	2.5 ml	Timoptol XE
	Eye drops 0.5%, gel forming – 1% DV Sep-16 to 2019	3.78	2.5 ml	Timoptol XE

VARIOUS

190	DIMERCAPTOSUCCINIC ACID (amended example brand) Cap 100 mg			e.g. PCNZ, Optimus Healthcare, Chemet Pharmaceutical-Compounding NZ-
	Cap 200 mg			e.g. PCNZ, Optimus Healthcare, Chemet Pharmaceutical-Compounding NZ-

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 June 2016

ALIMENTARY TRACT AND METABOLISM

13	ALUMINIUM HYDROXIDE WITH MAGNESIUM HYDROXIDE AND SIMETHICONE (delisting) Oral liq 200 mg with magnesium hydroxide 200 mg and simethicone 20 mg per 5 ml.....			<i>e.g. Mylanta</i>
	Note – Aluminium hydrochloride with magnesium hydroxide and simethicone oral liq 200 mg with magnesium hydroxide 200 mg and simethicone 20 mg per 5 ml to be delisted from 1 August 2016.			
16	COLLOIDAL BISMUTH SUBCITRATE Tab 120 mg	14.51	50	Gastrodenol
16	BISMUTH TRIOXIDE (delisting) Tab 120 mg	32.50	112	De-Nol
	Note – De-Nol tab 120 mg to be delisted from 1 January 2017.			
23	THYMOL GLYCERIN Compound, BPC – 1% DV Aug-16 to 2019.....	9.15	500 ml	PSM
26	CALCITRIOL (↓ price and addition of HSS) Cap 0.25 mcg – 1% DV Aug-16 to 2019	9.95	100	Calcitriol-AFT
	Cap 0.5 mcg – 1% DV Aug-16 to 2019	18.39	100	Calcitriol-AFT
	Note – Airflow calcitriol cap 0.25 mcg and 0.5 mcg to be delisted from 1 August 2016.			

CARDIOVASCULAR SYSTEM

42	METOPROLOL SUCCINATE (HSS delayed) Tab long-acting 23.75 mg – 1% DV Nov-16 Jun-16 to 2018.....	2.39	90	Metoprolol - AFT CR
	Tab long-acting 47.5 mg – 1% DV Nov-16 Jun-16 to 2018.....	3.48	90	Metoprolol - AFT CR
	Tab long-acting 95 mg – 1% DV Nov-16 Jun-16 to 2018.....	5.73	90	Metoprolol - AFT CR
	Tab long-acting 190 mg – 1% DV Nov-16 Jun-16 to 2018.....	11.54	90	Metoprolol - AFT CR
	Note – Metoprolol – AFT CR tab long-acting 23.75 mg, 47.5 mg, 95 mg and 190 mg, 30 tablet pack, delisting remains at 1 June 2016.			
42	METOPROLOL TARTRATE Tab 50 mg – 1% DV Aug-16 to 2018	4.64	100	Apo-Metoprolol
	Tab 100 mg – 1% DV Aug-16 to 2018	6.09	60	Apo-Metoprolol
	Note – Lopresor tab 50 mg and 100 mg to be delisted from 1 August 2016.			

DERMATOLOGICALS

53	CETOMACROGOL WITH GLYCEROL (↓ price and addition of HSS) Crm 90% with glycerol 10% – 1% DV Aug-16 to 2019.....	2.82	500 ml	Pharmacy Health Sorbolene with Glycerin
		3.87	1,000 ml	Pharmacy Health Sorbolene with Glycerin
	Note – healthE crm 90% with glycerol 10%, 500 ml, 1 bottle to be delisted from 1 August 2016.			

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 June 2016 (continued)

GENITO-URINARY SYSTEM

59	PROGESTERONE (addition of HSS) → Cap 100 mg – 1% DV Aug-16 to 2019.....	16.50	30	Utrogestan
----	--	-------	----	------------

MUSCULOSKELETAL SYSTEM

102	ROCURONIUM BROMIDE (↓ price and addition of HSS) Inj 10 mg per ml, 5 ml vial – 1% DV Aug-16 to 2019.....	25.95	10	DBL Rocuronium Bromide
-----	---	-------	----	---------------------------

NERVOUS SYSTEM

105	APOMORPHINE HYDROCHLORIDE (delisting) Inj 10 mg per ml, 2 ml ampoule.....	119.00	5	Apomine
Note – Apomine inj 10 mg per ml, 2 ml ampoule to be delisted from 1 August 2016.				
106	LISURIDE HYDROGEN MALEATE (delisting) Tab 200 mcg.....	25.00	30	Dopergin
Note – Dopergin tab 200 mcg to be delisted from 1 September 2016.				

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

137	OXALIPLATIN (HSS reinstated) Inj 5 mg per ml, 10 ml vial – 1% DV Jun-16 to 2018	13.32	1	Oxaliccord
	Inj 5 mg per ml, 20 ml vial – 1% DV Jun-16 to 2018	16.00	1	Oxaliccord

151	SILTUXIMAB → Inj 100 mg vial – 1% DV Jun-16 to 2018	770.57	1	Sylvant
	→ Inj 400 mg vial – 1% DV Jun-16 to 2018	3,082.33	1	Sylvant

Restricted

Initiation

Haematologist or rheumatologist

Re-assessment required after 6 months

All of the following:

1. Patient has severe HHV-8 negative idiopathic multicentric Castlemans Disease; and
2. Treatment with an adequate trial of corticosteroids has proven ineffective; and
3. Siltuximab is to be administered at doses no greater than 11 mg/kg every 3 weeks.

Continuation

Haematologist or rheumatologist

Re-assessment required after 12 months

The treatment remains appropriate and the patient has sustained improvement in inflammatory markers and functional status.

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 June 2016 (continued)

RESPIRATORY SYSTEM AND ALLERGIES

178 TIOTROPIUM BROMIDE (amended restriction)

Note: tiotropium treatment must not be used if the patient is also receiving treatment with subsidised inhaled glycopyrronium or umeclidinium.

→ Soln for inhalation 2.5 mcg per dose	70.00	60 dose	Spiriva Respimat
→ Powder for inhalation 18 mcg per dose	70.00	30 dose	Spiriva

Restricted

Initiation

All of the following:

- 1 To be used for the long-term maintenance treatment of bronchospasm and dyspnoea associated with COPD; and
- 2 In addition to standard treatment, the patient has trialed a short acting bronchodilator dose of at least 40 µg ipratropium q.i.d for one month; and
- 3 Either:
the patient's breathlessness according to the Medical Research Council (UK) dyspnoea scale is:
3.1 Grade **3 4** (stops for breath after walking about 100 meters or after a few minutes on the level); or
3.2 Grade **4 5** (too breathless to leave the house, or breathless when dressing or undressing); and
- 4 Actual FEV₁ as a % of predicted, must be below 60%; and
- 5 Either:
5.1 Patient is not a smoker (for reporting purposes only); or
5.2 Patient is a smoker and has been offered smoking cessation counselling; and
- 6 The patient has been offered annual influenza immunization.

SENSORY ORGANS

184 OLOPATADINE			
Eye drops 0.1%	17.00	5 ml	Patanol

Effective 1 May 2016

ALIMENTARY TRACT AND METABOLISM

20 GALSULFASE

→ Inj 1 mg per ml, 5 ml vial – 1% DV May-16 to 2018	2,234.00	1	Naglazyme
--	----------	---	------------------

Restricted

Initiation

Metabolic physician

Re-assessment required after 12 months

Both:

- 1 The patient has diagnosis of mucopolysaccharidosis VI; and
- 2 Either:
2.1 Diagnosis confirmed by demonstration of N-acetyl galactosamine-4-sulfatase (arylsulfatase B) deficiency confirmed by either an enzyme activity assay in leukocytes or skin fibroblasts; or
2.2 Detection of two disease causing mutations and patient has a sibling who is known to have mucopolysaccharidosis VI.

Continuation

Metabolic physician

Re-assessment required after 12 months

All of the following:

continued...

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 May 2016 (continued)

continued...

1. The treatment remains appropriate for the patient and the patient is benefiting from treatment; and
2. Patient has not had severe infusion-related adverse reactions which were not preventable by appropriate pre-medication and/or adjustment of infusion rates; and
3. Patient has not developed another life threatening or severe disease where the long term prognosis is unlikely to be influenced by Enzyme Replacement Therapy (ERT); and
4. Patient has not developed another medical condition that might reasonably be expected to compromise a response to ERT.

CARDIOVASCULAR SYSTEM

40	PHENTOLAMINE MESYLATE (new presentation) Inj 5 mg per ml, 1 ml ampoule			
42	METOPROLOL SUCCINATE (↓ price)			
	Tab long-acting 23.75 mg	0.80	30	Metoprolol - AFT CR
	Tab long-acting 47.5 mg	1.16	30	Metoprolol - AFT CR
	Tab long-acting 95 mg	1.91	30	Metoprolol - AFT CR
	Tab long-acting 190 mg	3.85	30	Metoprolol - AFT CR
	Note – Metoprolol – AFT CR tab long-acting, all strengths of the 30 tab pack size, to be delisted from 1 June 2016.			
48	MILRINONE (new listing and addition of HSS) Inj 1 mg per ml, 10 ml ampoule – 1% DV Jul-16 to 2018	300.30	10	Milrinone Generic Health

GENITO-URINARY SYSTEM

57	INTRA-UTERINE DEVICE (new listing) IUD 35.5 mm length × 19.6 mm width.....	31.60	1	Choice Load 375
----	---	-------	---	-----------------

HORMONE PREPARATIONS

61	CINACALCET (new listing) → Tab 30 mg	403.70	28	Sensipar
	Restricted Initiation Nephrologist or endocrinologist <i>Re-assessment required after 6 months</i> Either:			
	1 All of the following:			
	1.1 The patient has been diagnosed with a parathyroid carcinoma (see Note); and			
	1.2 The patient has persistent hypercalcaemia (serum calcium ≥ 3 mmol/L) despite previous first-line treatments including bisphosphonates and sodium thiosulfate; and			
	1.3 The patient is symptomatic; or			
	2 All of the following:			
	2.1 The patient has been diagnosed with calciphylaxis (calcific uraemic arteriopathy); and			
	2.2 The patient has symptomatic (e.g. painful skin ulcers) hypercalcaemia (serum calcium ≥ 3 mmol/L); and			
	2.3 The patient's condition has not responded to previous first-line treatments including bisphosphonates and sodium thiosulfate.			
	Continuation Nephrologist or endocrinologist			

continued...

→ Restriction
(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 May 2016 (continued)

continued...

Both:

- 1 The patient's serum calcium level has fallen to < 3mmol/L; and
- 2 The patient has experienced clinically significant symptom improvement.

Note: this does not include parathyroid adenomas unless these have become malignant.

INFECTIONS

71	GENTAMICIN SULPHATE (additional pack size) Inj 40 mg per ml, 2 ml ampoule – 1% DV Sep-15 to 2018	30.00	50	Pfizer
74	AMOXICILLIN WITH CLAVULANIC ACID (addition of HSS) Tab 500 mg with clavulanic acid 125 mg – 1% DV Aug-16 to 2017	1.95	20	Augmentin
Note – Curam Duo tab 500 mg with clavulanic acid 125 mg to be delisted from 1 August 2016.				
93	PEGYLATED INTERFERON ALFA-2A (delisting) Inj 135 mcg prefilled syringe Inj 135 mcg prefilled syringe (4) with ribavirin tab 200 mg (112) Note – Pegylated interferon alfa-2a inj 135 mcg prefilled syringe, and inj 135 mcg prefilled syringe (4) with ribavirin tab 200 mg (112) to be delisted from 1 July 2016			

NERVOUS SYSTEM

105	APOMORPHINE HYDROCHLORIDE (new listing) Inj 10 mg per ml, 2 ml ampoule	119.00	5	Movapo
124	BUSPIRONE HYDROCHLORIDE (new listing and addition of HSS) Tab 5 mg – 1% DV Jul-16 to 2018	23.80	100	Orion
	Tab 10 mg – 1% DV Jul-16 to 2018	14.96	100	Orion
Note – Pacific Buspirone tab 5 mg and 10 mg to be delisted from 1 July 2016.				

SENSORY ORGANS

183	CHLORAMPHENICOL (↓ price and addition of HSS) Eye oint 1% – 1% DV Jul-16 to 2019	2.48	4 g	Chlorsig
187	BIMATOPROST (new listing and addition of HSS) Eye drops 0.03% – 1% DV Jul-16 to 2018	3.65	3 ml	Bimatoprost Actavis

VARIOUS

190	DIMERCAPTOSUCCINIC ACID (addition of example brand) Cap 100 mg			<i>e.g. Pharmaceutical Compounding NZ</i>
190	DIMERCAPTOSUCCINIC ACID (new presentation) Cap 200 mg			<i>e.g. Pharmaceutical Compounding NZ</i>

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 May 2016 (continued)

191	ISOPROPYL ALCOHOL (delisting)			
	Soln 70%, 500 ml.....	5.00	1	PSM
		60.00	12	PSM

Note – PSM isopropyl alcohol soln 70%, 500 ml, 1 bottle and 12 bottle packs, to be delisted from 1 July 2016.

SPECIAL FOODS

206	FAT-MODIFIED FEED (new listing)			
	Powder 12.9 g protein, 69.1 g carbohydrate and 12.9 g fat per 100 g, 400 g can			<i>e.g. Monogen</i>
210	HIGH FAT FORMULA (amended presentation description)			
	Powder 14.4 g 15.25 g protein, 2.9 g 3 g carbohydrate and 69.2 g 73 g fat per 100 g, can.....	35.50	300 g	Ketocal 4:1 (Unflavoured) Ketocal 4:1 (Vanilla)

Effective 1 April 2016

ALIMENTARY TRACT AND METABOLISM

15	MISOPROSTOL (new listing and addition of HSS)			
	Tab 200 mcg – 1% DV Jun-16 to 2019	41.50	120	Cytotec
16	OMEPRAZOLE (↑ price)			
	Inj 40 mg ampoule with diluent	33.65	5	Dr Reddy's Omeprazole

CARDIOVASCULAR SYSTEM

41	DIGOXIN (new listing and addition of HSS)			
	Tab 62.5 mcg – 1% DV Jun-16 to 2019	6.67	240	Lanoxin PG
	Tab 250 mcg – 1% DV Jun-16 to 2019	14.52	240	Lanoxin
42	METOPROLOL SUCCINATE			
	Tab long-acting 190 mg – 1% DV Jun-16 to 2018	11.54	90	Metoprolol - AFT CR
	Note – Metoprolol – AFT CR tab long-acting 190 mg, 30 tab pack, to be delisted from 1 June 2016.			
44	FUROSEMIDE [FRUSEMIDE] (↓ price and addition of HSS)			
	Inj 10 mg per ml, 2 ml ampoule – 1% DV Jun-16 to 2019	1.20	5	Frusemide-Claris
44	PERHEXILINE MALEATE (addition of HSS)			
	Tab 100 mg – 1% DV Jun-16 to 2019	62.90	100	Pexsig
47	ISOSORBIDE MONONITRATE (addition of HSS)			
	Tab long-acting 40 mg – 1% DV Jun-16 to 2019	7.50	30	Ismo 40 Retard



(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 April 2016 (continued)

GENITO-URINARY SYSTEM

59	DINOPROSTONE (amended presentation description)			
	Vaginal gel 1 mg in 3 g 2.5 ml	52.65	1	Prostin E2
	Vaginal gel 2 mg in 3 g 2.5 ml	64.60	1	Prostin E2

HORMONE PREPARATIONS

69	DESMOPRESSIN ACETATE (↓ price and addition of HSS)			
	→ Tab 100 mcg – 1% DV Jun-16 to 2019	25.00	30	Minirin
	→ Tab 200 mcg – 1% DV Jun-16 to 2019	54.45	30	Minirin

INFECTIONS

73	CLARITHROMYCIN			
	→ Grans for oral liq 50 mg per ml	23.12	50 ml	Klacid
	Note – Klacid grans for oral liq 25 mg per ml, 70 ml to be delisted from 1 October 2016.			

MUSCULOSKELETAL SYSTEM

95	LEFLUNOMIDE (delisting)			
	Tab 100 mg	54.44	3	Arava
	Note – Arava tab 100 mg to be delisted from 1 April 2016.			
102	CLOSTRIDIUM BOTULINUM TYPE A TOXIN			
	Inj 300 u vial	388.50	1	Dysport

NERVOUS SYSTEM

107	PROPOFOL (↓ price addition of HSS)			
	Inj 10 mg per ml, 20 ml vial – 10% DV Jun-16 to 2019	5.27	5	Provive MCT-LCT 1%
107	PROPOFOL (new listing)			
	Inj 10 mg per ml, 50 ml vial – 10% DV Jun-16 to 2019	24.50	10	Fresofol 1% MCT/LCT
	Inj 10 mg per ml, 100 ml vial – 10% DV Jun-16 to 2019	49.00	10	Fresofol 1% MCT/LCT
107	PROPOFOL (delisting)			
	Inj 10 mg per ml, 20 ml ampoule	7.60	5	Fresofol 1%
	Inj 10 mg per ml, 20 ml vial	42.00	5	Diprivan
	Inj 10 mg per ml, 50 ml syringe	47.00	1	Diprivan
	Inj 10 mg per ml, 50 ml vial	4.00	1	Fresofol 1%
		25.00		Provive MCT-LCT 1%
				Diprivan
	Inj 10 mg per ml, 100 ml vial	7.60	1	Fresofol 1%
				Provive MCT-LCT 1%

Note – Fresofol 1% inj 10 mg per ml, 20 ml ampoule, 50 ml vial and 100 ml vial to be delisted from 1 June 2016.

Note – Diprivan inj 10 mg per ml, 20 ml vial, 50 ml syringe, and 50 ml vial to be delisted from 1 June 2016.

Note – Provive MCT-LCT 1% inj 10 mg per ml, 50 ml vial, 1 inj pack size and 100 ml vial, 1 inj pack size, to be delisted from 1 June 2016.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 April 2016 (continued)

108	BUPIVACAINE HYDROCHLORIDE WITH FENTANYL Inj 0.625 mg with fentanyl 2 mcg per ml, 200 ml bag		
123	FLUPHENAZINE DECANOATE Inj 25 mg per ml, 2 ml ampoule		<i>e.g. Modecate</i>

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

137	OXALIPLATIN (HSS suspended) Inj 5 mg per ml, 10 ml vial		
	– 1% DV Mar-16 to 2018 31/3/16	13.32	1 Oxaliccord
	Inj 5 mg per ml, 20 ml vial		
	– 1% DV Mar-16 to 2018 31/3/16	16.00	1 Oxaliccord

Note – HSS for Oxaliccord inj 5 mg per ml, 10 ml and 20 ml vials has been suspended and will be reinstated from 1 June 2016 until 30 June 2018.

RESPIRATORY SYSTEM AND ALLERGIES

176	BEE VENOM (new listing) → Maintenance kit - 6 vials 120 mcg freeze dried venom, with diluent		
176	PAPER WASP VENOM (new listing) → Treatment kit – 6 vials 120 mcg freeze dried venom, with diluent		
176	YELLOW JACKET WASP VENOM (new listing) → Treatment kit – 6 vials 120 mcg freeze dried venom, with diluent		

SENSORY ORGANS

188	POLYVINYL ALCOHOL (↓ price and addition of HSS) Eye drops 1.4% – 1% DV Jun-16 to 2019	2.62	15 ml Vistil
	Eye drops 3% – 1% DV Jun-16 to 2019	3.68	15 ml Vistil Forte

Note – Liquifilm Tears eye drops 1.4% and Liquifilm Forte eye drops 3% to be delisted from 1 June 2016.

VARIOUS

192	IODISED OIL (↑ price) Inj 38% w/w (480 mg per ml), 10 ml ampoule	191.00	1 Lipiodol Ultra Fluid
-----	---	--------	------------------------

SPECIAL FOODS

205	AMINO ACID ORAL FEED (new listing) → Powder 11 g protein, 62 g carbohydrate and 1 g fat per sachet	4.50	80 g Vivonex TEN
205	AMINO ACID ORAL FEED (delisting) → Powder 11.5 g protein, 61.7 g carbohydrate and 0.8 g fat per sachet	4.50	80.4 g Vivonex TEN

Note – Vivonex TEN powder, 80.4 g pack size, to be delisted from 1 June 2016.

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 April 2016 (continued)

213	ENTERAL FEED 1 KCAL/ML			
	→ Liquid 4 g protein, 13.6 g carbohydrate and 3.4 g fat per 100 ml, bottle	2.65	500 ml	Osmolite RTH
	→ Liquid 4 g protein, 13.6 g carbohydrate and 3.4 g fat per 100 ml, can	1.24	250 ml	Osmolite
	Note – Osmolite RTH 500 ml and Osmolite 250 ml to be delisted from 1 June 2016.			

Index

Pharmaceuticals and brands

A	
Aciclovir	11
Aluminium hydroxide with magnesium hydroxide and simethicone.....	17
Amiloride hydrochloride.....	9
Amino acid oral feed	24
Amoxicillin	10
Amoxicillin with clavulanic acid	21
Apo-Amiloride.....	9
Apo-Amoxi.....	10
Apo-Cilazapril/Hydrochlorothiazide	9
Apo-Metoprolol	17
Apomine	18
Apomorphine hydrochloride	18, 21
Apo-Oxybutynin	9
Apo-Ropinirole.....	11, 12
Arava	23
Aromasin	13
Arrow-Morphine LA.....	12
Arrow-Sertraline.....	12
Augmentin	21
AZT.....	10
B	
Bee venom.....	24
Bimatoprost	21
Bimatoprost Actavis	21
Bismuth trioxide	17
Bortezomib	13
Bupivacaine hydrochloride with fentanyl	24
Bupirone hydrochloride.....	21
C	
Calcitriol	17
Calcitriol-AFT	17
Carmellose sodium with pectin and gelatine.....	8
Cefaclor.....	10
Cetomacrogol with glycerol.....	17
Chloramphenicol	21
Chlorsig	21
Choice Load 375.....	20
Cilazapril with hydrochlorothiazide.....	9
Cinacalcet.....	20
Clarithromycin.....	23
Clindamycin.....	10
Clindamycin ABM.....	10
Clomiphene citrate	10
Clostridium botulinum type a toxin.....	23
Colloidal bismuth subcitrate	17
Cyklokapron.....	8
Cytotec	22
D	
Dalacin C	10
DBL Rocuronium Bromide.....	18
De-Nol	17
Desmopressin acetate.....	23
Dexamethasone phosphate.....	10
DHC Continus	12
Diamide Relief.....	8
Digoxin	22
Dihydrocodeine tartrate	12
Dimercaptosuccinic acid	16, 21
Dimethicone.....	9
Dinoprostone	23
Diprivan	23
Dipyridamole.....	8
Dopergin.....	18
Dr Reddy's Omeprazole.....	8, 22
Duovisc	16
Dysport.....	23
E	
Enteral feed 1 kcal/ml.....	25
Eptacog alfa.....	8
Exemestane	13
F	
Fat-modified feed	22
Fluconazole.....	10
Fluconazole-Claris.....	10
Fluphenazine decanoate	24
Fresofol 1%.....	23
Fresofol 1% MCT/LCT	23
Frusamide.....	22
Frusamide-Claris	22
Furosemide.....	22
G	
Galsulfase.....	19
Gastrodenol	17
Gentamicin sulphate.....	21
Glycopyrronium bromide	8
H	
Harvoni	11
Healon	15
Healon 5	15
Healon GV.....	15
healthE Dimethicone 5%.....	9
healthE Urea Cream.....	9
High fat formula	22
Hyaluronic acid	15, 16
I	
Intra-uterine device.....	20
Iodised oil	24
Ismo 40 Retard	22
Isopropyl alcohol.....	22
Isoptin	9

Index

Pharmaceuticals and brands

Isosorbide mononitrate.....	22	Ondansetron-Claris	12
Itraconazole	10	Ondansetron Kabi.....	12
Itrazole.....	10	Opdivo	13
K		Osmolite	25
Ketocal 4:1 (Unflavoured).....	22	Osmolite RTH.....	25
Ketocal 4:1 (Vanilla).....	22	Oxalliccord.....	18, 24
Klacid	23	Oxaliplatin	18, 24
L		Oxybutynin.....	9
Lactulose	8	Oxycodone hydrochloride.....	12
Laevolac	8	P	
Lamotrigine.....	12	Paper wasp venom	24
Lanoxin	22	Paritaprevir, ritonavir and ombitasvir with dasabuvir.....	11
Lanoxin PG	22	Paritaprevir, ritonavir and ombitasvir with dasabuvir and ribavirin	11
Ledipasvir with sofosbuvir.....	11	Patanol	19
Leflunomide.....	23	Pegylated interferon alfa-2a.....	21
Levomepromazine hydrochloride.....	12	Penicillin V.....	10
Lipiodol Ultra Fluid	24	Perhexiline maleate	22
Lisuride hydrogen maleate.....	18	Pexsig.....	22
Loperamide hydrochloride.....	8	Pfizer Exemestane.....	13
Lorafix	15	Pharmacy Health Sorbolene with Glycerin.....	17
Loratadine.....	15	Pheburane	8
Lovir.....	11	Phenoxymethylpenicillin	10
M		Phentolamine mesylate	20
Mabthera	14	Polyvinyl alcohol	24
Methotrexate	13	Pramipexole hydrochloride	11
Methotrexate Sandoz.....	13	Progesterone	18
Metoprolol - AFT CR.....	17, 20, 22	Propofol.....	23
Metoprolol succinate.....	17, 20, 22	Prostin E2.....	23
Metoprolol tartrate.....	9, 17	Provive MCT-LCT 1%.....	23
Milrinone.....	20	Pytazen SR	8
Milrinone Generic Health.....	20	R	
Minirin	23	Ramipex	11
Misoprostol.....	22	Ranbaxy-Cefaclor.....	10
Moderate.....	24	Rapamune	15
Morphine sulphate.....	12	Recombinant factor VIIa	8
Motetis	11	Retrovir.....	10
Motrig.....	12	Rituximab	14
Movapo	21	Rocuronium bromide	18
Mylan Clomiphen	10	Ropinirole hydrochloride.....	11, 12
N		S	
Naglazyme.....	19	Sensipar	20
Neostigmine metilsulfate with glycopyrronium bromide	11	Sertraline	12
Nivolumab	13	Siltuximab	18
Norpress.....	12	Sirolimus	15
Nortriptyline hydrochloride.....	12	Slow-Lopresor	9
NovoSeven RT	8	Sodium chloride.....	9
O		Sodium hyaluronate	15
Olopatadine.....	19	Sodium hyaluronate with chondroitin sulphate	16
Omeprazole.....	8, 22	Sodium phenylbutyrate.....	8
Ondansetron	12		

Index

Pharmaceuticals and brands

Spiriva	15, 19	Utrogestan	18
Spiriva Respimat	15, 19	V	
Sylvant	18	Velcade.....	13
Synacthen.....	10	Verapamil hydrochloride.....	9
Synacthen Depot.....	10	Vfend.....	10
T		Viekira Pak.....	11
Tenoxicam.....	11	Viekira Pak-RBV.....	11
Terazosin.....	9	Viscoat	16
Tetrabenazine.....	11	Vistil	24
Tetracosactide	10	Vistil Forte.....	24
Tetracosactrin.....	10	Vivonex TEN.....	24
Thymol glycerin	17	Voriconazole	10
Tilcotil.....	11	W	
Timolol	16	Water.....	9
Timoptol XE	16	Y	
Tiotropium bromide.....	15, 19	Yellow jacket wasp venom	24
Tranexamic acid.....	8	Z	
U		Zidovudine	10
Urea.....	9		



Email: enquiry@pharmac.govt.nz

www.pharmac.govt.nz/medicines/hospital-pharmaceuticals

Pharmaceutical Management Agency
Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand
Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz

ISSN 1172-3694 (Print) - ISSN 1179-3708 (Online)

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the Update.

If Undelivered, Return To: PO Box 10254, Wellington 6143, New Zealand